Liu T, Bai J, Ying S, et al. - This study was undertaken to investigate the clinical response and safety of omalizumab for treating patients with normocomplementaemic urticarial vasculitis (NUV) in a real-world setting. Data were obtained from a single center. Researchers enrolled a total of five patients with NUV who received omalizumab therapy. The clinical efficacy was assessed by the patient's self-assessment instrument urticarial vasculitis activity score and Dermatology Life Quality Index during a 24-week study period. The results revealed that omalizumab may be a potential choice in the treatment of patients with NUV in real-world life.